{"id":206566,"date":"2026-08-17T12:14:17","date_gmt":"2026-08-17T06:44:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=206566"},"modified":"2026-08-17T12:14:19","modified_gmt":"2026-08-17T06:44:19","slug":"novelix-pharma-q1-fy27-results-pat-1-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/","title":{"rendered":"Novelix Pharma Q1 FY27 Results: Revenue Grows 65% to Rs 36 Crore, PAT Surges to Rs 1 Crore"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Novelix Pharma Q1 FY27: Revenue Rs 36 Cr (+65.15% YoY). PAT Rs 1 Cr (+1001.78%). Gross profit Rs 1 Cr vs Rs 0.17 Cr (+625.8%). Standalone. CMP Rs 73.97 on Aug 13, 2026.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Novelix Pharma Q1 FY27 results showed standalone revenue growing 65% to Rs 36 crore and PAT surging approximately 1002% to Rs 1 crore as the pharmaceutical company crossed manufacturing scale breakeven thresholds.<\/p>\n<\/div>\n<p>Novelix Pharma Q1 FY27 results showed the pharmaceutical formulations company posting 65.15% revenue growth to Rs 36 crore from Rs 22 crore in Q1 FY26, reflecting new product launches, expanded distribution, or institutional pharma market entry.<\/p>\n<p>The Novelix Pharma Q1 FY27 results showed gross profit jumping 625% from Rs 0.17 crore to Rs 1 crore on 65% revenue growth \u2014 a scale economy crossover where higher API procurement volumes and better capacity utilisation dramatically reduced per-unit manufacturing costs.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=novelix-pharma-q1fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Novelix_Pharma_Q1_FY27_Financial_Highlights\" title=\"Novelix Pharma Q1 FY27 Financial Highlights\">Novelix Pharma Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Novelix_Pharma_Q1_FY27_Performance_Analysis\" title=\"Novelix Pharma Q1 FY27 Performance Analysis\">Novelix Pharma Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Key_Business_Factors_in_Q1_FY27\" title=\"Key Business Factors in Q1 FY27\">Key Business Factors in Q1 FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Pharmaceutical_Scale_Economies\" title=\"Pharmaceutical Scale Economies\">Pharmaceutical Scale Economies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Generic_Pharma_Growth\" title=\"Generic Pharma Growth\">Generic Pharma Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Operating_Leverage\" title=\"Operating Leverage\">Operating Leverage<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#FY27_Outlook\" title=\"FY27 Outlook\">FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Novelix_Pharma_Stock_Performance\" title=\"Novelix Pharma Stock Performance\">Novelix Pharma Stock Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Regulatory_Risk\" title=\"Regulatory Risk\">Regulatory Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#API_Price_Volatility\" title=\"API Price Volatility\">API Price Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Competition_from_Larger_Pharma\" title=\"Competition from Larger Pharma\">Competition from Larger Pharma<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Frequently_Asked_Questions_on_Novelix_Pharma_Q1_FY27_Results\" title=\"Frequently Asked Questions on Novelix Pharma Q1 FY27 Results\">Frequently Asked Questions on Novelix Pharma Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#When_were_Novelix_Pharma_Q1_FY27_results_announced\" title=\"When were Novelix Pharma Q1 FY27 results announced?\">When were Novelix Pharma Q1 FY27 results announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#What_was_Novelix_Pharma_revenue_in_Q1_FY27\" title=\"What was Novelix Pharma revenue in Q1 FY27?\">What was Novelix Pharma revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#What_was_Novelix_Pharma_PAT_in_Q1_FY27\" title=\"What was Novelix Pharma PAT in Q1 FY27?\">What was Novelix Pharma PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Why_did_PAT_surge_1002_on_65_revenue_growth\" title=\"Why did PAT surge 1002% on 65% revenue growth?\">Why did PAT surge 1002% on 65% revenue growth?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Did_Novelix_Pharma_declare_a_dividend\" title=\"Did Novelix Pharma declare a dividend?\">Did Novelix Pharma declare a dividend?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#What_is_the_outlook\" title=\"What is the outlook?\">What is the outlook?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/novelix-pharma-q1-fy27-results-pat-1-crore\/#Is_Novelix_Pharma_a_good_investment\" title=\"Is Novelix Pharma a good investment?\">Is Novelix Pharma a good investment?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Novelix_Pharma_Q1_FY27_Financial_Highlights\"><\/span><strong>Novelix Pharma Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<thead style=\"background: #1F4E79; color: #ffffff;\">\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 (Rs Crore)<\/th>\n<th>Q1 FY26 (Rs Crore)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>36.00<\/td>\n<td>22.00<\/td>\n<td>+65.15%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>1.00<\/td>\n<td>0.17<\/td>\n<td>+625.8%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit \/ PAT<\/td>\n<td>1.00<\/td>\n<td>0.11<\/td>\n<td>+1001.78%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Novelix_Pharma_Q1_FY27_Performance_Analysis\"><\/span><strong>Novelix Pharma Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to track Novelix Pharma live financials and Q1 FY27 results<\/strong><\/a><\/p>\n<p>Novelix Pharma Q1 FY27 results demonstrate pharmaceutical operating leverage. Revenue crossing a scale threshold reduces per-unit API and manufacturing costs, driving the disproportionate 625% gross profit improvement on 65% revenue growth.<\/p>\n<p>PAT surging 1002% from Rs 0.11 crore to Rs 1 crore confirms the company is now meaningfully above its profitability breakeven point in pharmaceutical manufacturing.<\/p>\n<p>At Rs 36 crore quarterly revenue and Rs 1 crore PAT (2.8% margin), Novelix Pharma has significant headroom for margin improvement as revenue scales further \u2014 pharma manufacturing margins typically improve substantially at higher volumes.<\/p>\n<p>India&#8217;s growing generic pharmaceutical market and government healthcare spending expansion provide structural demand tailwinds for formulations companies like Novelix Pharma.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Q1_FY27\"><\/span><strong>Key Business Factors in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Pharmaceutical_Scale_Economies\"><\/span><strong>Pharmaceutical Scale Economies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Higher API procurement volumes and better capacity utilisation drove the 625% gross profit improvement on 65% revenue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Generic_Pharma_Growth\"><\/span><strong>Generic Pharma Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s domestic and export generic pharma demand drives Novelix Pharma&#8217;s revenue growth trajectory.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Leverage\"><\/span><strong>Operating Leverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT surging 1002% on 65% revenue growth reflects pharmaceutical operating leverage above the breakeven threshold.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Novelix Pharma has not declared a dividend for Q1 FY27. The company is reinvesting in product development and distribution expansion.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook\"><\/span><strong>FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The FY27 outlook is positive. Continued revenue growth with improving pharmaceutical manufacturing margins would significantly increase PAT from the Q1 FY27 results base.<\/p>\n<p>Regulatory approvals, API cost management, and competition from larger pharma companies are the key risk factors.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Novelix_Pharma_Stock_Performance\"><\/span><strong>Novelix Pharma Stock Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Novelix Pharma share price live and stay updated on quarterly results.<\/em><\/p>\n<p>Novelix Pharma shares traded at Rs 73.97 on August 13, 2026, up 1.34%, reflecting positive market reception of the Q1 FY27 results growth trajectory.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_Risk\"><\/span><strong>Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New product launches require regulatory approvals. Delays would slow revenue growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"API_Price_Volatility\"><\/span><strong>API Price Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Active pharmaceutical ingredient costs are subject to global supply fluctuations from key sourcing markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competition_from_Larger_Pharma\"><\/span><strong>Competition from Larger Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Generic formulations markets are competitive. Larger companies have scale and distribution advantages.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Novelix Pharma Q1 FY27 results show impressive 65% revenue growth to Rs 36 crore and PAT surging 1002% to Rs 1 crore as pharmaceutical scale economies kicked in.<\/p>\n<p>Strong growth trajectory but investors should assess product pipeline and competitive positioning. Consult a SEBI-registered advisor.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Novelix_Pharma_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Novelix Pharma Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Novelix_Pharma_Q1_FY27_results_announced\"><\/span><strong>When were Novelix Pharma Q1 FY27 results announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> August 13, 2026, standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Novelix_Pharma_revenue_in_Q1_FY27\"><\/span><strong>What was Novelix Pharma revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Rs 36 crore, up 65.15% from Rs 22 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Novelix_Pharma_PAT_in_Q1_FY27\"><\/span><strong>What was Novelix Pharma PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Rs 1 crore, up approximately 1002% from Rs 0.11 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_PAT_surge_1002_on_65_revenue_growth\"><\/span><strong>Why did PAT surge 1002% on 65% revenue growth?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Scale economies in pharmaceutical manufacturing dramatically reduce per-unit API and production costs at higher volumes, crossing the profitability breakeven threshold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Novelix_Pharma_declare_a_dividend\"><\/span><strong>Did Novelix Pharma declare a dividend?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend for Q1 FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook\"><\/span><strong>What is the outlook?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Positive with continued revenue growth. Monitor regulatory pipeline and competition.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Novelix_Pharma_a_good_investment\"><\/span><strong>Is Novelix Pharma a good investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Strong growth story. Assess product portfolio and regulatory status. Consult a SEBI-registered advisor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novelix Pharma Q1 FY27 results showed standalone revenue growing 65% to Rs 36 crore and PAT surging approximately 1002% to Rs 1 crore as pharmaceutical manufacturing scale economies delivered dramatic margin improvement.<\/p>\n","protected":false},"author":35,"featured_media":206565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-206566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["206565"],"_edit_lock":["1786949062:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["76"],"rank_math_title":["Novelix Pharma Q1 FY27 Results: Revenue Rs 36 Cr, PAT Surges 1002%"],"rank_math_description":["Novelix Pharma Q1 FY27 results: Revenue grew 65% to Rs 36 crore and PAT surged approximately 1002% to Rs 1 crore. Manufacturing scale economies drove the turnaround. Full analysis."],"rank_math_focus_keyword":["Novelix Pharma Q1 FY27 results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["37861"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/novelix-pharma-q1-fy27-results-pat-1-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/206566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=206566"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/206566\/revisions"}],"predecessor-version":[{"id":206581,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/206566\/revisions\/206581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/206565"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=206566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=206566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=206566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}